<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19880" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Congestive Heart Failure and Pulmonary Edema</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>King</surname>
            <given-names>Kevin C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goldstein</surname>
            <given-names>Samuel</given-names>
          </name>
          <aff>Advocate Lutheran General Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kevin King declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samuel Goldstein declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19880.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Heart failure is a chronic, progressive condition where the heart is unable to pump blood effectively to meet the body's needs, leading to fluid buildup, particularly in the lungs, causing pulmonary edema. This condition is a leading cause of morbidity and mortality, particularly among the elderly, and is often associated with comorbidities such as hypertension, coronary artery disease, and diabetes. The increasing prevalence of heart failure is driven by the aging population and improved survival rates from cardiovascular conditions. Early detection and appropriate management are crucial in reducing hospitalizations and improving the quality of life for patients.</p>
        <p>In this course, healthcare professionals enhance their competence in recognizing and managing heart failure and pulmonary edema. They learn to assess symptoms accurately, utilize diagnostic tools like echocardiography, and apply treatment strategies, including diuretics, vasodilators, and beta-blockers. Collaboration with an interprofessional team, including cardiologists, nurses, and pharmacists, ensures comprehensive care is highlighted; this collaboration improves treatment adherence and optimizes patient outcomes by preventing exacerbations and reducing the need for hospital readmissions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the early signs and symptoms of heart failure, including dyspnea, fatigue, and fluid retention.</p></list-item><list-item><p>Differentiate between heart failure with reduced ejection fraction and heart failure with preserved ejection fraction based on clinical and echocardiographic findings.</p></list-item><list-item><p>Screen high-risk individuals, such as those with hypertension or coronary artery disease, for the potential development of heart failure.</p></list-item><list-item><p>Communicate interprofessional team strategies for improving care coordination and communication to advance the treatment and management of heart failure to improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19880&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19880">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19880.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Heart failure is a growing public health problem that is now the most common cause of hospitalizations in the United States among patients aged 65 and older. The growing prevalence of heart failure is primarily attributed to an aging population and a rise in risk factors such as hypertension and diabetes.&#x000a0;Healthcare professionals should be familiar with the pathophysiology, presentation, and treatment of heart failure because of the morbidity, mortality, and projected increased prevalence of the condition.<xref ref-type="bibr" rid="article-19880.r1">[1]</xref><xref ref-type="bibr" rid="article-19880.r2">[2]</xref><xref ref-type="bibr" rid="article-19880.r3">[3]</xref></p>
        <p>Heart failure is a clinical syndrome and encompasses a constellation of symptoms secondary to impaired cardiac function; there are numerous etiologies for impaired heart function. The causative factors for heart failure are generally divided into structural or functional categories. Patients who have heart failure can also be classified based on the stage or degree of heart failure and symptoms, including episodes of&#x000a0;acute exacerbation and pulmonary edema. Heart failure can be divided into&#x000a0;2 broad categories: heart&#x000a0;failure with preserved ejection fraction (HFpE) and heart failure with reduced ejection fraction (HFrEF). The incidence of HFpEF increases with age, and most cases of heart failure in older patients are due to HFpEF.<xref ref-type="bibr" rid="article-19880.r1">[1]</xref><xref ref-type="bibr" rid="article-19880.r3">[3]</xref>&#x000a0;&#x000a0;&#x000a0;</p>
        <p>Acute decompensated heart failure (ADHF) is a common and potentially fatal cause of cardiac dysfunction that can present with acute respiratory distress. In ADHF, pulmonary edema&#x000a0;and the rapid accumulation of fluid within the interstitial and alveolar spaces&#x000a0;lead&#x000a0;to significant dyspnea and respiratory decompensation. There&#x000a0;are many different causes of pulmonary edema, though cardiogenic pulmonary edema is usually a&#x000a0;result of acutely elevated cardiac filling pressures.<xref ref-type="bibr" rid="article-19880.r4">[4]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-19880.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>In the United States, there are many causes of heart failure&#x02014;the&#x000a0;most common of which is coronary artery disease. Identifying the risk factors for heart failure is important because this condition is preventable. Acknowledging the preventable nature of heart failure, the American College of Cardiology and the American Heart Association have updated their classification systems to identify patients without structural abnormalities early, enabling timely and appropriate treatment. Treatment of systolic and diastolic hypertension concurrently in alignment with contemporary guidelines reduces the risk of heart failure by&#x000a0;approximately 50%.<xref ref-type="bibr" rid="article-19880.r1">[1]</xref></p>
        <p>
<bold>Risk Factors for Heart Failure&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Coronary artery disease (CAD)</p>
          </list-item>
          <list-item>
            <p>Connective tissue disorders (ie, rheumatoid arthritis, scleroderma, systemic lupus erythematosus)</p>
          </list-item>
          <list-item>
            <p>Endocrine disorders (ie, diabetes mellitus, thyroid function disorders, growth hormone deficiency)</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>High-output conditions (ie, anemia, Paget disease)</p>
          </list-item>
          <list-item>
            <p>Valvular heart disease</p>
          </list-item>
          <list-item>
            <p>Metabolic causes (ie, obesity)</p>
          </list-item>
          <list-item>
            <p>Myocarditis (ie, secondary to human immunodeficiency virus and acquired immunodeficiency syndrome, medications, or viruses)</p>
          </list-item>
          <list-item>
            <p>Infiltrative disorders (ie, amyloidosis, sarcoidosis)</p>
          </list-item>
          <list-item>
            <p>Peripartum cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Stress cardiomyopathy (Takotsubo)</p>
          </list-item>
          <list-item>
            <p>Valvular heart disease</p>
          </list-item>
          <list-item>
            <p>Medications (ie, amphetamines, anabolic steroids)</p>
          </list-item>
          <list-item>
            <p>Tachycardia induced cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Toxins (ie, cocaine, alcohol)</p>
          </list-item>
          <list-item>
            <p>Nutritional deficiency (ie, L-carnitine deficiency, thiamine)&#x000a0;<xref ref-type="bibr" rid="article-19880.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Risk Factors for Acute Heart Failure and&#x000a0;Flash Pulmonary Edema</bold>
</p>
        <p>Acute heart<bold>&#x000a0;</bold>failure is the&#x000a0;worsening of heart failure symptoms to the point that the patient requires intensification of therapy and&#x000a0;intravenous&#x000a0;treatment. Acute heart failure can be dramatic and rapid in onset, such as flash pulmonary edema, or&#x000a0;more gradual with the worsening of symptoms over time until a critical point of decompensation is reached. For those with a history of preexisting heart failure, there is often a clear trigger for decompensation.<xref ref-type="bibr" rid="article-19880.r3">[3]</xref><xref ref-type="bibr" rid="article-19880.r4">[4]</xref></p>
        <p>
<bold>Potential Triggers of Acute Decompensated Heart Failure&#x000a0;and Flash Pulmonary Edema&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Arrhythmia</p>
          </list-item>
          <list-item>
            <p>CAD</p>
          </list-item>
          <list-item>
            <p>Infection</p>
          </list-item>
          <list-item>
            <p>Worsening&#x000a0;hypertension (ie, hypertensive crisis)</p>
          </list-item>
          <list-item>
            <p>Medication&#x000a0;non-adherence</p>
          </list-item>
          <list-item>
            <p>Acute renal artery stenosis</p>
          </list-item>
          <list-item>
            <p>Left ventricular diastolic dysfunction</p>
          </list-item>
          <list-item>
            <p>Obstructive sleep apnea</p>
          </list-item>
          <list-item>
            <p>Stress (Takotsubo) cardiomyopathy&#x000a0;<xref ref-type="bibr" rid="article-19880.r3">[3]</xref><xref ref-type="bibr" rid="article-19880.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19880.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Heart failure is&#x000a0;a major public health problem. This condition is now the most common cause of hospitalization in the&#x000a0;United States among patients aged 65 and older, and approximately 91,500 new cases of heart failure are diagnosed each year. The increasing prevalence of heart failure&#x000a0;is most likely&#x000a0;secondary to the aging of the population, increased risk factors, better outcomes for acute coronary syndrome survivors, and a reduction in mortality secondary to improved management of chronic conditions. Further, incidence rates for heart failure increase with age for both sexes.<xref ref-type="bibr" rid="article-19880.r1">[1]</xref><xref ref-type="bibr" rid="article-19880.r2">[2]</xref><xref ref-type="bibr" rid="article-19880.r3">[3]</xref><xref ref-type="bibr" rid="article-19880.r5">[5]</xref></p>
        <p>The lifetime risk of developing heart failure for&#x000a0;those 40 and older residing in the&#x000a0;United States is 20%. The risk and incidence of heart failure continue&#x000a0;to increase from 20 per&#x000a0;1000&#x000a0;people aged 60 to 65 to over 80 per 1000 people aged 80 and older. There are also differences in risk for heart failure based on the population, with Black individuals having the highest risk and greater 5-year mortality for heart failure&#x000a0;than the White population in the&#x000a0;United States. The&#x000a0;European Society of Cardiology states that the prevalence of heart failure is 1% to 2% and rises to greater than 10% in the population of those aged 70 and older.<xref ref-type="bibr" rid="article-19880.r1">[1]</xref><xref ref-type="bibr" rid="article-19880.r3">[3]</xref>&#x000a0;</p>
        <p>
<bold>Heart Failure Statistics&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Heart failure survival has improved over time, yet&#x000a0;the absolute 5-year mortality rates from diagnosis for heart failure have remained at 50%</p>
          </list-item>
          <list-item>
            <p>Heart failure&#x000a0;is the number&#x000a0;1 diagnosis among all hospitalizations, and the cost of annual heart failure care exceeds $30 billion every year.</p>
          </list-item>
          <list-item>
            <p>Most of the cost spent on heart failure patients is for&#x000a0;hospitalizations and readmissions.<xref ref-type="bibr" rid="article-19880.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Acute Heart Failure&#x000a0;</bold>
</p>
        <p>Although&#x000a0;consensus guidelines tend to&#x000a0;use the term heart failure to refer to those with established chronic disease, acute heart failure is defined as a more rapid onset of signs and symptoms or the gradual worsening of chronic symptoms that necessitate intravenous treatment. Acute heart failure exacerbation that requires hospitalization tends to occur in the older adult population, with a mean age of 79 years and a slightly higher preponderance of women affected than men.<xref ref-type="bibr" rid="article-19880.r1">[1]</xref><xref ref-type="bibr" rid="article-19880.r2">[2]</xref><xref ref-type="bibr" rid="article-19880.r3">[3]</xref> Data from the United Kingdon National Heart Failure Audit show mortality rates of approximately 10% during the index&#x000a0;admission, 30-day postdischarge mortality of 6.5%, and 1-year mortality of 30%.<xref ref-type="bibr" rid="article-19880.r3">[3]</xref></p>
      </sec>
      <sec id="article-19880.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Heart failure can arise from various cardiovascular or metabolic abnormalities. Still, in most cases, clinical symptoms are due to left ventricular dysfunction and may be preserved or reduced when left ventricular dysfunction is present. The ejection fraction is a key measure often used to select patients for clinical trials and guide therapeutic decisions. In contrast, pulmonary edema seen in acute decompensated heart failure results from the dysregulation of pulmonary fluid homeostasis, disrupting the balance of forces controlling fluid movement into the alveolar space.<xref ref-type="bibr" rid="article-19880.r4">[4]</xref><xref ref-type="bibr" rid="article-19880.r6">[6]</xref></p>
      </sec>
      <sec id="article-19880.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Heart failure is predominately a clinical diagnosis. The presentation&#x000a0;of heart failure may&#x000a0;vary based on each&#x000a0;patient; therefore, it&#x000a0;is essential to consider the following during the history and physical:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>History:</bold>&#x000a0;If the patient has a history of past heart failure, ask if this is the same presentation as when they had previous episodes of&#x000a0;heart failure or an acute decompensation.</p>
          </list-item>
          <list-item>
            <p><bold>Symptom Causes:</bold> Consider noncardiac and other causes of the patient's symptoms, as it is important to ensure a broad differential diagnosis and avoid anchoring bias, premature closer, and diagnostic inertia.</p>
          </list-item>
          <list-item>
            <p><bold>Heart failure symptoms:</bold>
<list list-type="bullet"><list-item><p>Increasing dyspnea (on exertion, on lying flat or at rest, exercise intolerance)</p></list-item><list-item><p>Increasing leg swelling, ascites, edema</p></list-item><list-item><p>Increased body weight</p></list-item><list-item><p>Palpitations, automatic implantable cardioverter-defibrillator&#x000a0;shocks (associated with worse prognosis)</p></list-item><list-item><p>Chest pain, fatigue</p></list-item><list-item><p>Duration of Illness, recent or frequent hospitalizations for heart failure</p></list-item><list-item><p>Medications or diet changes</p></list-item><list-item><p>Anorexia, cachexia, or early satiety (associated with worse prognosis)</p></list-item><list-item><p>Symptoms of transient ischemic attack or thromboembolism (indicate a possible need for anticoagulation)</p></list-item><list-item><p>Social history and family history (to assess for possible familial cardiomyopathy, alcohol, or other cause</p></list-item><list-item><p>Travel history (exposure risk to some tropical diseases)<bold>&#x000a0;</bold><xref ref-type="bibr" rid="article-19880.r1">[1]</xref><xref ref-type="bibr" rid="article-19880.r6">[6]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>The physical examination should include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Vital signs: </bold>Assess blood pressure, heart rate, temperature, oxygen saturation, and respiratory rate. Vital signs are important in helping develop and refine the differential diagnosis and help the healthcare professional tailor the physical examination better.</p>
          </list-item>
          <list-item>
            <p><bold>Check patient weight:&#x000a0;</bold>The patient's weight and body mass index should be checked during each office visit. The information can be used to track response to treatment and the potential progression of heart failure or acute decompensated heart failure. Losing weight can also be a warning sign of worsening heart failure.</p>
          </list-item>
          <list-item>
            <p><bold>Assessment of jugulovenous distension:&#x000a0;</bold>Jugulovenous distension can be a marker for fluid overload. The patient should lie at a 45-degree angle in bed to get an accurate assessment.</p>
          </list-item>
          <list-item>
            <p><bold>Pulse:&#x000a0;</bold>Assess the regularity and strength of the pulse.</p>
          </list-item>
          <list-item>
            <p><bold>Cardiac Examination</bold>
<list list-type="bullet"><list-item><p>Extra heart sounds (ie, S3 is associated with a worse prognosis), murmurs</p></list-item><list-item><p>Size and location of maximal cardiac impulse (can suggest ventricular enlargement if displaced)</p></list-item><list-item><p>Presence of right ventricular heave</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Pulmonary Examination:</bold> Check respiratory rate,&#x000a0;rhonchi, and rales (note: pleural effusions can mask and reduce breath sounds, and rhonchi or rales may be less prominent).</p>
          </list-item>
          <list-item>
            <p><bold>Abdominal examination: </bold>Check for ascites, hepatomegaly, hepatojugular reflux.</p>
          </list-item>
          <list-item>
            <p><bold>Lower extremity examination: </bold>Assess for peripheral edema and skin temperature (cool lower extremities may suggest worse cardiac output).<xref ref-type="bibr" rid="article-19880.r1">[1]</xref><xref ref-type="bibr" rid="article-19880.r6">[6]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19880.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold> Classification of Heart Failure</bold>
</p>
        <p>Classification is one of the key determinants of evaluating and treating heart failure. When a patient is in acute or decompensated heart failure, our focus is&#x000a0;on&#x000a0;expeditious identification and treatment&#x000a0;of&#x000a0;life threats. Different classification schemes are available when evaluating chronic heart failure. The classification scheme used to categorize the type and degree of heart failure is based on the presentation and affects the&#x000a0;treatment and prognosis of the condition. Heart failure classification schemes are generally based on&#x000a0;1 of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Anatomic findings (ie, heart failure with different degrees of ejection fraction)</p>
          </list-item>
          <list-item>
            <p>The chamber of the heart involved (including functional)</p>
          </list-item>
          <list-item>
            <p>Symptoms of the patient</p>
          </list-item>
        </list>
        <p>All heart failure patients should also be classified based on the American College Cardiology Foundation (ACCF)/American Heart Association (AHA) stages of heart failure, a New York Heart Association (NYHA) functional classification.<xref ref-type="bibr" rid="article-19880.r1">[1]</xref><xref ref-type="bibr" rid="article-19880.r6">[6]</xref></p>
        <p>
<bold>ACCF/AHA Stages of Heart Failure</bold>
</p>
        <p>The risk of heart failure defines the ACC/AHA stages of heart failure, the presence of active heart failure, and whether structural heart disease is present. The higher the classification, the greater the treatment and interventions the patient may require.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>A: No structural heart disease present, high risk for heart failure, and asymptomatic</p>
          </list-item>
          <list-item>
            <p>B: Structural heart disease present, asymptomatic</p>
          </list-item>
          <list-item>
            <p>C: Structural heart disease present and current or previous symptoms of heart failure</p>
          </list-item>
          <list-item>
            <p>D: Heart failure that is refractory and requires specialized interventions&#x000a0;<xref ref-type="bibr" rid="article-19880.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>NYHA Functional Classification of Heart Failure</bold>
</p>
        <p>The NYHA classification is a functional classification of heart failure and is based on how much the patients' symptoms limit their physical activity and to what degree physical activity can cause the person to become symptomatic. The grading scale is from I (least severe)to grade IV (the most severe) where the patient cannot perform physical activity and has symptoms at rest.<xref ref-type="bibr" rid="article-19880.r6">[6]</xref></p>
        <p>
<bold>Diagnostic Tests</bold>
</p>
        <p>Testing for heart failure in patients should be&#x000a0;focused on the patient's symptoms, clinical suspicion, and pre-existing or current stage of heart failure. Ordering multiple routine tests should be avoided in all patients with heart failure. Basic tests that should merit consideration for all patients evaluated for heart failure are the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum electrolytes and kidney function</p>
          </list-item>
          <list-item>
            <p>Complete blood count</p>
          </list-item>
          <list-item>
            <p>Lipid level</p>
          </list-item>
          <list-item>
            <p>Liver function tests</p>
          </list-item>
          <list-item>
            <p>Troponin level if there is concern that myocardial injury is the cause of symptoms</p>
          </list-item>
          <list-item>
            <p>Thyroid-stimulating hormone</p>
          </list-item>
          <list-item>
            <p>An electrocardiogram&#x000a0;</p>
          </list-item>
        </list>
        <p>Other tests that may be considered based on the severity and classification of the patient's condition are:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Chest x-rays</bold>&#x000a0;assess for signs of pulmonary congestion or edema in acute decompensated heart failure (see Image.&#x000a0;Congestive Heart Failure, Radiograph).</p>
          </list-item>
          <list-item>
            <p><bold>Biomarkers</bold>&#x000a0;are used to assess patients with more complex symptoms than acute heart failure (ie, B-type natriuretic peptide&#x000a0;and N-terminal pro-B-type natriuretic peptide).</p>
          </list-item>
        </list>
        <p>For further information on the recommendations for evaluating heart failure, please see the American Heart Association and New York Heart Association classification-based heart failure guidelines.<xref ref-type="bibr" rid="article-19880.r1">[1]</xref><xref ref-type="bibr" rid="article-19880.r2">[2]</xref><xref ref-type="bibr" rid="article-19880.r6">[6]</xref></p>
      </sec>
      <sec id="article-19880.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Treatment of Acute Decompensated Heart Failure and Pulmonary Edema</bold>
</p>
        <p>The focus of treatment for patients with heart failure is dependent on the severity of the symptoms and the stage of heart failure. When patients are in acute decompensated heart failure or flash pulmonary edema,&#x000a0;the most important focus&#x000a0;for therapeutic interventions is the enhancement of hemodynamic status through the reduction&#x000a0;of&#x000a0;vascular congestion and improving preload, afterload, and myocardial contractility.<xref ref-type="bibr" rid="article-19880.r2">[2]</xref>&#x000a0;In flash pulmonary edema, where there is a rapid onset of heart failure, the initial&#x000a0;management and treatment goals are very similar to acute decompensated heart failure. Treatment options for acute decompensated heart failure and flash pulmonary edema are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>ABCs:&#x000a0;</bold>As with all patients, it is crucial to assess airway, breathing, and circulation in the initial evaluation and initiate appropriate management based on patient status. In decompensated heart failure, patients should be hooked up to cardiorespiratory monitoring, have IV access and oxygen administered if hypoxic or tachypnoeic, have an electrocardiogram performed, and have labs drawn based on clinical suspicion and patient&#x000a0;condition.</p>
          </list-item>
          <list-item>
            <p><bold>Diuretics: </bold>Most patients presenting with heart failure have a form of volume overload. AHA and ACC guidelines recommend intravenous loop diuretic administration to treat fluid overload. Intravenous administration is preferred over oral diuretics to maximize the bioavailability of the medication and clinical effects. Furosemide is a common treatment for acute decompensated heart failure and flash-pulmonary edema because of its&#x000a0;anti-vasoconstrictor and diuretic effects.<xref ref-type="bibr" rid="article-19880.r2">[2]</xref><xref ref-type="bibr" rid="article-19880.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Vasodilators:&#x000a0;</bold>Patients with acute decompensated heart failure with hypertension and acute pulmonary edema can benefit from treatment with vasodilators. Most vasodilators promote smooth muscle relaxation and vasodilatation to reduce preload and afterload through the cyclic guanine monophosphate pathway. Vasodilation relieves pulmonary vascular congestion and improves left ventricular preload and afterload. The common&#x000a0;vasodilator medications&#x000a0;used are nitroglycerin and sodium nitroprusside.<xref ref-type="bibr" rid="article-19880.r2">[2]</xref><xref ref-type="bibr" rid="article-19880.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Nitroglycerin can be given transdermally, sublingually, or intravenously, depending on the patient's condition. In acute decompensation or flash pulmonary edema, nitroglycerin is best given sublingually or intravenously to allow for titration of effect.<xref ref-type="bibr" rid="article-19880.r2">[2]</xref><xref ref-type="bibr" rid="article-19880.r6">[6]</xref></p>
              </list-item>
              <list-item>
                <p>Sodium nitroprusside is only given intravenously. Patients with renal dysfunction treated with sodium nitroprusside may need to have their cyanide levels monitored. Check with your pharmacist about guidelines for monitoring cyanide levels.<xref ref-type="bibr" rid="article-19880.r2">[2]</xref><xref ref-type="bibr" rid="article-19880.r6">[6]</xref></p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><bold>Ionotropic Medications: </bold>Additional treatment options for patients in cardiogenic shock or who have signs of end-organ dysfunction secondary to hypoperfusion. Inotropes&#x000a0;should only be used as&#x000a0;a&#x000a0;treatment adjunct&#x000a0;in acute decompensated heart failure since&#x000a0;data from&#x000a0;the ADHERE registry suggest increased mortality with use. Dobutamine and mllrinone are 2 inotropes that are more commonly used. Dobutamine is preferable for patients who are beta-blocker-naive, while milrinone is preferred for patients previously taking oral beta blockers who experience acute decompensation.<xref ref-type="bibr" rid="article-19880.r2">[2]</xref><xref ref-type="bibr" rid="article-19880.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Continuous Positive Airway Pressure (CPAP) and Bilevel Positive Airway Pressure (BIPAP):</bold> These are noninvasive methods of respiratory support to treat respiratory insufficiency secondary to pulmonary vascular congestion and&#x000a0;pulmonary edema. The use of CPAP and BIPAP has reduced the need for intubation and mechanical ventilation in heart failure patients with acute respiratory decompensation. In situations where CPAP and BIPAP are ineffective in improving the patient's respiratory status, early intubation and mechanical ventilation should be considered to help prevent further decompensation and progression of symptoms.<xref ref-type="bibr" rid="article-19880.r7">[7]</xref><xref ref-type="bibr" rid="article-19880.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Coronary revascularization:&#x000a0;</bold>When performed in appropriately selected patients, revascularization can reduce mortality and morbidity by improving diastolic and systolic dysfunction. According to the AHAs 2013 congestive heart failure guidelines, coronary artery revascularization may be indicated as an intervention for heart failure patients with angina, left ventricle dysfunction, and CAD. Interventional cardiology should be consulted early for patients according to AHA recommendations.<xref ref-type="bibr" rid="article-19880.r2">[2]</xref><xref ref-type="bibr" rid="article-19880.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Admission to inpatient service for further treatment and evaluation:&#x000a0;</bold>Patients being treated for flash pulmonary edema should be admitted to the hospital with the level of monitoring and care appropriate for each case. For select patients with acute decompensated heart failure, it may be possible to treat them at home, depending on the severity of symptoms.<xref ref-type="bibr" rid="article-19880.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>
<bold>The Medical Management of Heart Failure&#x02013;Risk Factor Modification and Prevention of Acute Decompensation</bold>
</p>
        <p>While acute decompensated heart failure and flash pulmonary edema can be dramatic and require intensive care and aggressive therapy, the main focus of heart failure management is on helping prevent the progression of the disease and mitigate episodes of acute exacerbation. Medical practitioners often use the American Heart Association and the New York Heart Association stages of heart failure to guide the evidence-based treatment of heart failure. Treatment of early stages of chronic heart failure usually focuses on risk factor modification, and as the disease process progresses, it starts to include more aggressive interventions.</p>
        <list list-type="bullet">
          <list-item>
            <p>Risk factor modification
<list list-type="bullet"><list-item><p>Dietary and lifestyle changes, such as decreased salt intake, reduced obesity, and smoking cessation</p></list-item><list-item><p>Tighter control and management of hypertension, diabetes dyslipidemia, and other chronic diseases that can exacerbate CHF</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>More aggressive intervention for those with a higher degree of CHF</p>
          </list-item>
          <list-item>
            <p>Echocardiography for patients with a higher risk of left ventricular ejection fraction reduction</p>
          </list-item>
          <list-item>
            <p>Implantable cardiac defibrillator placement, when indicated in patients with ischemic cardiomyopathy at high risk of sudden death</p>
          </list-item>
        </list>
        <p>For further information on the medical management of chronic heart failure, please refer to the American Heart Association and New York Heart Association guidelines.<xref ref-type="bibr" rid="article-19880.r1">[1]</xref><xref ref-type="bibr" rid="article-19880.r2">[2]</xref><xref ref-type="bibr" rid="article-19880.r1">[1]</xref><xref ref-type="bibr" rid="article-19880.r6">[6]</xref></p>
        <p><bold>Advanced Treatment Strategies for End-Stage Congestive Heart Failure</bold>For select patients with end-stage heart failure, which is refractory to other treatment strategies, the option of mechanical circulatory support and cardiac transplantation should be considered. In mechanical circulatory support, for example, a left ventricular assist device is often used as a bridge therapy until a heart transplant is available.&#x000a0;In certain situations, mechanical circulatory support is utilized as destination therapy.&#x000a0;For patients who are not candidates for mechanical circulatory support or cardiac transplantation, palliative care and continuous inotropic support should be considered and discussed with the patient&#x000a0;(see <bold>Image.</bold> Congestive Heart Failure).<xref ref-type="bibr" rid="article-19880.r1">[1]</xref><xref ref-type="bibr" rid="article-19880.r10">[10]</xref></p>
      </sec>
      <sec id="article-19880.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>When patients present with acute decompensated heart failure or flash pulmonary edema, there are many different diagnoses to consider based on the risk factors for heart failure alone. Also important to consider are other potentially life-threatening causes of heart failure.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Sepsis:&#x000a0;</bold>Patients with sepsis are at risk of multiorgan system failure. Approximately&#x000a0;1 out of 3 patients with sepsis present with reversible left ventricular systolic dysfunction reduced ejection fracture, and 1 out of 2 patients with sepsis have left ventricular or right ventricular diastolic dysfunction. The cardiac dysfunction associated with sepsis can result in significantly increased mortality. Left ventricular diastolic dysfunction is associated with an increased mortality risk of 80%, and right ventricular diastolic dysfunction is associated with a 60% increased mortality.<xref ref-type="bibr" rid="article-19880.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Acute respiratory distress syndrome: </bold>This condition&#x000a0;is characterized by acute respiratory failure and diffuse pulmonary infiltrates, which could potentially mimic flash pulmonary edema.<xref ref-type="bibr" rid="article-19880.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Neurological causes:&#x000a0;</bold>Hemispheric and hippocampal brain infarcts are associated with heart failure and sudden cardiac death. Infarct of certain areas of the brain tissue can result in a sympathetic storm, and loss of vasomotor homeostasis precipitates neurogenic pulmonary edema (see <bold>Image.</bold>&#x000a0;Key Features in the Pathophysiology of Neurogenic Pulmonary Edema).<xref ref-type="bibr" rid="article-19880.r12">[12]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Pulmonary embolism:&#x000a0;</bold>While a massive pulmonary embolism can cause acute cardiac dysfunction secondary to obstruction of blood flow, post-pulmonary embolism syndrome may also present with heart failure-type symptoms. Postpulmonary embolism syndrome and reduced exercise tolerance have been associated with reduced left ventricular ejection fraction, arrhythmia, valvular dysfunction, and left ventricular diastolic dysfunction.<xref ref-type="bibr" rid="article-19880.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Acute coronary syndrome:&#x000a0;</bold>Acute coronary syndrome or myocardial infarction is a common cause of acute decompensated heart failure.&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19880.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The diagnosis of heart failure alone can be associated with a mortality rate greater than many cancers. Despite advances made in heart failure treatments, the prognosis of the condition worsens over time, resulting in frequent hospital admissions and premature death. Results from one recent study showed that patients recently diagnosed with new-onset heart failure had a mortality rate of 20.2% at&#x000a0;1 year and 52.6% at&#x000a0;5 years. The&#x000a0;1- and 5-year mortality rates also increase significantly based on the patient's age. Another study had results showing that the 1- and 5-year mortality for patients at age 60 is 7.4% and 24.4%, and for patients at age 80 is 19.5% and 54.4%.&#x000a0;The mortality rates were similar when evaluated across different cardiac ejection fractions.<xref ref-type="bibr" rid="article-19880.r5">[5]</xref><xref ref-type="bibr" rid="article-19880.r10">[10]</xref><xref ref-type="bibr" rid="article-19880.r14">[14]</xref></p>
        <p>The prognosis is worse for those with heart failure who are hospitalized; those with heart failure commonly require repeat hospitalizations and develop an intolerance for standard treatments as the disease progresses. Data from the United States Medicare beneficiaries hospitalized during 2006 showed 30-day and 1-year mortality rates postadmission of 10.8% and 30.7,% respectively. Mortality outcomes at&#x000a0;1 year also demonstrate a clear relationship with age and increase from 22% for those aged 65 to 42.7% for patients aged 85 and older.<xref ref-type="bibr" rid="article-19880.r5">[5]</xref><xref ref-type="bibr" rid="article-19880.r10">[10]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-19880.s11" sec-type="Complications">
        <title>Complications</title>
        <p>&#x000a0;<bold>Potential Complications of Heart Failure</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Worsening clinical status despite aggressive therapy</p>
          </list-item>
          <list-item>
            <p>Associated renal impairment and organ dysfunction can compromise heart failure treatment efforts</p>
          </list-item>
          <list-item>
            <p>Recurrent hospitalizations for heart failure or, most commonly, associated co-morbidities, with resultant financial and personal costs to patients and families</p>
          </list-item>
          <list-item>
            <p>The progressive loss of ability&#x000a0;to carry out activities of daily life</p>
          </list-item>
          <list-item>
            <p>Increased morbidity and mortality from the date of the patient's initial diagnosis of heart failure <xref ref-type="bibr" rid="article-19880.r1">[1]</xref><xref ref-type="bibr" rid="article-19880.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19880.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Effective treatment of comorbidities and risk factor reduction can decrease the chance of developing heart failure. Patient education should be focused on ensuring compliance with prescribed evidence-based treatments.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hypertension:&#x000a0;</bold>Effective treatment of systolic and diastolic hypertension can reduce the risk of heart failure by approximately 50%</p>
          </list-item>
          <list-item>
            <p><bold>Diabetes: </bold>This condition<bold>&#x000a0;</bold>is directly associated with the development of heart failure, independent of other associated clinical conditions.</p>
          </list-item>
          <list-item>
            <p><bold>Alcohol:</bold> Heavy alcohol use is associated with heart failure.</p>
          </list-item>
          <list-item>
            <p><bold>Metabolic syndromes: </bold>Following&#x000a0;treatments based on evidence-based guidelines to decrease the risk of heart failure (ie, lipid disorders) is vital.</p>
          </list-item>
          <list-item>
            <p><bold>Patient education: </bold>Education&#x000a0;regarding dietary salt restriction and fluid restriction is imperative.<xref ref-type="bibr" rid="article-19880.r1">[1]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19880.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Treating heart failure and acute decompensated heart failure is challenging despite the use of maximal evidence-based therapy based on the stage of heart failure. Given the limited effect of current treatment strategies on the progression of heart failure, it is important to identify ways to maximize patient outcomes and quality of care by the interprofessional team. Patients at potential risk for heart failure based on comorbidities or other identified risk factors should receive appropriate evidence-based preventative counseling and treatments. When applicable, the primary care clinician who may be the most involved in managing the patient's risk factors should&#x000a0;consult&#x000a0;other specialists, including cardiologists, endocrinologists, pharmacists, cardiology nurses, and nutritionists, to ensure they provide the best advice and treatment for their patients. Nurses monitor patients, provide education, and collaborate with clinicians and the healthcare team to improve outcomes. Pharmacists review medications, inform patients and their families about potential adverse events, and monitor compliance. Given the propensity of patients with heart failure to require recurrent admissions, often because of non heart failure-related conditions, the collaboration between inpatient and outpatient services can be of benefit in the continuity of care and help promote improved outcomes.</p>
      </sec>
      <sec id="article-19880.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19880&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19880">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/congestive-heart-failure-and-pulmonary-edema-chf/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19880">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19880/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19880">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-19880.s15">
        <fig id="article-19880.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Congestive Heart Failure, Radiograph. Chest radiographs help assess for signs of pulmonary congestion or edema in acute decompensated heart failure. Contributed by&#x000a0;S Bhimji, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cHF" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-19880.s16">
        <fig id="article-19880.image.f2" position="float" orientation="portrait">
          <caption>
            <p>&#x000a0;Key Features, Pathophysiology of Neurogenic Pulmonary Edema. This table details the key features seen in the pathophysiology of neurogenic pulmonary edema. Contributed by M Al-Dhahir, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CNS" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-19880.s17">
        <title>References</title>
        <ref id="article-19880.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gedela</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jonsson</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Heart Failure.</article-title>
            <source>S D Med</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>68</volume>
            <issue>9</issue>
            <fpage>403</fpage>
            <page-range>403-5, 407-9</page-range>
            <pub-id pub-id-type="pmid">26489162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19880.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsiao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Contemporary Treatment of Acute Heart Failure.</article-title>
            <source>Prog Cardiovasc Dis</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>367</fpage>
            <page-range>367-78</page-range>
            <pub-id pub-id-type="pmid">26764279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19880.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurmani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Squire</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Acute Heart Failure: Definition, Classification and Epidemiology.</article-title>
            <source>Curr Heart Fail Rep</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>385</fpage>
            <page-range>385-392</page-range>
            <pub-id pub-id-type="pmid">28785969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19880.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rimoldi</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Yuzefpolskaya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Allemann</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Messerli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Flash pulmonary edema.</article-title>
            <source>Prog Cardiovasc Dis</source>
            <year>2009</year>
            <season>Nov-Dec</season>
            <volume>52</volume>
            <issue>3</issue>
            <fpage>249</fpage>
            <page-range>249-59</page-range>
            <pub-id pub-id-type="pmid">19917337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19880.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dharmarajan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology, Pathophysiology, and Prognosis of Heart Failure in Older Adults.</article-title>
            <source>Heart Fail Clin</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>417</fpage>
            <page-range>417-426</page-range>
            <pub-id pub-id-type="pmid">28602363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19880.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Geraci</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Horwich</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Masoudi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Riegel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Wilkoff</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Oct</month>
            <day>15</day>
            <volume>128</volume>
            <issue>16</issue>
            <fpage>1810</fpage>
            <page-range>1810-52</page-range>
            <pub-id pub-id-type="pmid">23741057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19880.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stoltzfus</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The role of noninvasive ventilation: CPAP and BiPAP in the treatment of congestive heart failure.</article-title>
            <source>Dimens Crit Care Nurs</source>
            <year>2006</year>
            <season>Mar-Apr</season>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>66</fpage>
            <page-range>66-70</page-range>
            <pub-id pub-id-type="pmid">16552275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19880.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bello</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Santis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Antonelli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Non-invasive ventilation in cardiogenic pulmonary edema.</article-title>
            <source>Ann Transl Med</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>18</issue>
            <fpage>355</fpage>
            <pub-id pub-id-type="pmid">30370282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19880.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Sunderland</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of hospital in the home treatment of acute decompensated congestive cardiac failure compared to traditional in-hospital treatment in older patients.</article-title>
            <source>Australas J Ageing</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>e77</fpage>
            <page-range>e77-e85</page-range>
            <pub-id pub-id-type="pmid">31325230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19880.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Habal</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Garan</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Long-term management of end-stage heart failure.</article-title>
            <source>Best Pract Res Clin Anaesthesiol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-166</page-range>
            <pub-id pub-id-type="pmid">29110789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19880.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caraballo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jaimes</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Organ Dysfunction in Sepsis: An Ominous Trajectory From Infection To Death.</article-title>
            <source>Yale J Biol Med</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>92</volume>
            <issue>4</issue>
            <fpage>629</fpage>
            <page-range>629-640</page-range>
            <pub-id pub-id-type="pmid">31866778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19880.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasad Hrishi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruby Lionel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Prathapadas</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Head Rules Over the Heart: Cardiac Manifestations of Cerebral Disorders.</article-title>
            <source>Indian J Crit Care Med</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>7</issue>
            <fpage>329</fpage>
            <page-range>329-335</page-range>
            <pub-id pub-id-type="pmid">31406441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19880.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dzikowska-Diduch</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kostrubiec</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kurnicka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lichodziejewska</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pacho</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miroszewska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Br&#x000f3;dka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Skowro&#x00144;ska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x00141;abyk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Go&#x00142;&#x00119;biowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pruszczyk</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>"The post-pulmonary syndrome - results of echocardiographic driven follow up after acute pulmonary embolism".</article-title>
            <source>Thromb Res</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>186</volume>
            <fpage>30</fpage>
            <page-range>30-35</page-range>
            <pub-id pub-id-type="pmid">31862573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19880.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Heart failure.</article-title>
            <source>Lancet</source>
            <string-date>2005 May 28-Jun 3</string-date>
            <volume>365</volume>
            <issue>9474</issue>
            <fpage>1877</fpage>
            <page-range>1877-89</page-range>
            <pub-id pub-id-type="pmid">15924986</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
